This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Identifying Changes in Blood (Potential Biomarkers) in Individuals With Drug-Induced Liver Injury

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University of North Carolina, Chapel Hill
ClinicalTrials.gov Identifier:
NCT01000766
First received: October 22, 2009
Last updated: April 15, 2017
Last verified: April 2017
  Purpose
The purpose of this study is to try to develop new blood tests that may help doctors identify if a drug is hurting a person's liver.

Condition
Drug Induced Liver Injury

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Identification of New Biomarkers of Drug Induced Liver Injury

Further study details as provided by University of North Carolina, Chapel Hill:

Biospecimen Retention:   Samples Without DNA
blood

Enrollment: 25
Actual Study Start Date: September 2009
Study Completion Date: December 2013
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts
Acute drug-induced liver injury

Detailed Description:
Our hypothesis is that there are liver-specific particles, called mRNA, that are identifiable in a person's blood sample during liver injury caused by some drugs. The purpose of this study is to try to develop new blood tests that may help doctors identify if a drug is hurting a person's liver, perhaps early in the process before significant injury or illness have occurred.
  Eligibility

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients will be identified in emergency rooms or inpatients at the University of North Carolina Memorial Hospital.
Criteria

Inclusion Criteria:

  • ALT > 200 IU/L at presentation to UNC Hospitals
  • Drug induced liver injury considered likely by admitting medical staff
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01000766

Locations
United States, North Carolina
University of North Carolina
Chapel Hill, North Carolina, United States, 27599
Sponsors and Collaborators
University of North Carolina, Chapel Hill
Investigators
Principal Investigator: Paul B Watkins, MD University of North Carolina, Chapel Hill
  More Information

Responsible Party: University of North Carolina, Chapel Hill
ClinicalTrials.gov Identifier: NCT01000766     History of Changes
Other Study ID Numbers: 50KR10957
Study First Received: October 22, 2009
Last Updated: April 15, 2017

Additional relevant MeSH terms:
Wounds and Injuries
Drug-Induced Liver Injury
Liver Diseases
Digestive System Diseases
Drug-Related Side Effects and Adverse Reactions
Chemically-Induced Disorders
Poisoning

ClinicalTrials.gov processed this record on August 18, 2017